Glenmark Pharmaceuticals Limited has informed the Exchange about Business Responsibility and Sustainability Report for F.Y. 2024-25

Glenmark Pharmaceuticals has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 as mandated under SEBI's Listing Regulations. On a standalone basis, the company reported turnover of INR 92,264.09 Mn with 51.39% (INR 47,416.62 Mn) coming from exports to 80+ countries. It operates 8 plants and 15 offices in India, plus 3 plants and 48 offices internationally, with 3 R&D centers at Sinnar, Taloja and Mahape. The workforce includes 11,952 permanent employees (92% male, 8% female) and 4,671 permanent workers. The board has 44% female representation (4 of 9 directors). The report identifies 10 material ESG issues including product quality and recalls, climate action, data privacy, and supply chain sustainability as key risks, while innovation, access to medicines, and human capital are flagged as opportunities. DNV Business Assurance India provided reasonable assurance on BRSR core indicators. Customer complaints rose sharply to 3,717 (from 2,666 in FY24), with 365 pending. Net worth stands at INR 245,039.56 Mn.